- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Shilpa Medicare Limited — Updates, 10-11-2025: General Updates
10-11-2025 | 12:46 pm
10-11-2025 | 12:46 pm
Shilpa Medicare's OERIS™ (once-weekly CINV injection) achieved positive Phase 3 results. It showed strong efficacy (89% complete response) & superior convenience/safety. A single dose offers 5-day antiemetic coverage. Targets a ~$375 Million market; global approvals next.
No comments yet. Be the first to comment!